薑黃素 Curcumin × 憂鬱症
結論：證據支持但有警示
L11 明確建議 publish_with_warning — honor L11 recommendation (B10 fix)
B 🟡 B 初步證據 附警語發布 🚨 high — heavy affiliate marketing in TW community
⚖️
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查原始分數 0.60
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
78%
證據方向大致一致
證據層級
E2
多篇高品質統合分析（≥2 篇一致）
▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.6
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
The efficacy and acceptability of curcumin for the treatment of depression or depressive symptoms: A systematic review and meta-analysis
結論：Curcumin produced a small but statistically significant reduction in depressive symptoms vs placebo. Pooled SMD = -0.32 (95% CI -0.50 to -0.13), I2 = 15%, n=594. Response rates favored curcumin (OR=3.20, 95% CI 1.28-7.99). Drop-out rates and adverse events did not differ from placebo. Authors graded overall evidence quality as low.
前往 PubMed
Curcumin for depression: a meta-analysis
結論：Pooled Hedges' g = -0.75 (95% CI -1.11 to -0.39, p<0.001) for depression — large effect favoring curcumin add-on to standard care. Anxiety symptom subset (5 trials, n=284): Hedges' g = -2.62 (95% CI -4.06 to -1.17). Authors caution that small individual sample sizes and heterogeneity warrant cautious interpretation.
前往 PubMed
Curcumin Reduces Depression in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial
結論：Curcumin arm showed significantly greater improvement in PHQ-9 depression severity vs placebo at 12 months (p=0.000001). Mechanistic secondary outcomes: higher serum serotonin, lower IL-1beta, IL-6 and TNF-alpha, and increased antioxidant activity in the curcumin group (all p<0.001). Largest and longest RCT to date in a metabolic-comorbid depressive population.
前往 PubMed
Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial
結論：Nano-curcumin reduced DASS-21 depression score from 16.7 (SD 3.1) to 15.3 (SD 2.6) vs placebo 17.5 (3.2) -> 17.3 (3.1); between-group p=0.02. Anxiety subscale also improved (p=0.009). Demonstrates that low-dose bioavailable nano-formulation can produce measurable antidepressant signal in subclinical/comorbid depression.
前往 PubMed
The effect of curcumin on postpartum depression and anxiety in primiparous women: a double-blind randomized placebo-controlled clinical trial
結論：Curcumin 500 mg/day for 8 weeks produced significantly greater reductions in postpartum depression and anxiety scores vs placebo, with improvements in mental-health and quality-of-life secondary outcomes. Extends evidence of curcumin's antidepressant signal into perinatal population; effect size not reported as SMD in abstract.
前往 PubMed
L4a US FDA
中性
— 本適應症無對應資料
L4b EU EFSA
謹慎
the Panel established an ADI for curcumin of 3 mg/kg bw/day 來源↗
L4c UK NHS
謹慎
Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. 來源↗
L4d TW TFDA / 衛福部
謹慎
薑黃素每人每日攝取量為每公斤體重0~3毫克，每日不超過200毫克為宜 來源↗
L4e WHO
中性
Rhizoma Curcumae Longae 來源↗
L5a NIH Office of Dietary Supplements
謹慎
We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. 來源↗
L5b Mayo Clinic
謹慎
limited data in small studies show its effectiveness in providing some improvement in depression 來源↗
L5c Cleveland Clinic
謹慎
curcumin may also increase levels of serotonin and dopamine, which are chemicals in your brain that regulate mood and other body functions. 來源↗
L5d Harvard Health
中性
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態
— 本適應症無對應資料
PTT · Dcard · Mobile01 彙整自公開論壇討論，非統計抽樣，僅反映社群風向。
廣告 / 業配密度 極高
低中高
📍立場總覽
台灣社群（PTT regimen／Health、Dcard 閒聊／美妝）對「薑黃素」討論量大，但幾乎全集中在護肝解酒、抗發炎關節、代謝減脂、美容與提神，幾乎沒有「為憂鬱症而吃」的真實使用經驗。憂鬱／抗憂鬱框架主要出現在商業健康媒體與部落格業配文，社群本身僅有零星「精神比較好」之類模糊回饋，屬未討論／無共識。
💬社群實感
無共識（針對憂鬱症幾無真實實測，社群討論集中於護肝、抗發炎、代謝與美容；少數人主觀回饋「精神／活力變好」，但非針對憂鬱症且多與疲勞改善混淆）
破解迷思 社群最常見的 5 個誤解
✓
事實把「吃了精神／活力變好」直接等同「抗憂鬱、改善憂鬱症」（社群實測多屬疲勞或解酒後的主觀感受，非情緒疾患療效）
✓
事實誤信商業媒體／部落格「薑黃素效果等同百憂解」標題（源自單一小型對照試驗的過度延伸，社群轉貼時常忽略樣本小、僅輔助參考）
✓
事實誤以為市售薑黃／薑黃粉產品薑黃素含量足以達到研究劑量（多數市售品濃度低、生物利用率差，未加吸收技術幾無研究等級攝取量）
✓
事實誤以為薑黃素可取代抗憂鬱處方藥或自行停藥（社群與證據皆不支持，風險高）
✓
事實誤以為劑量越高越好（高劑量易致反胃、噁心、腹瀉等腸胃不適）
🩹 社群通報的副作用
- 高劑量反胃、噁心、想吐
- 腹瀉、腸胃不適
- 少數人對高劑量薑黃出現過敏反應
- 與抗凝血劑（Warfarin、阿斯匹靈）交互作用之出血風險提醒
- 膽結石／膽道阻塞者慎用提醒
🏷️ 社群熱議品牌
依論壇被提及頻率，非銷售或品質排序。
- UNIQMAN（薑黃＋肝精，PTT／Dcard 應酬熬夜族常見）
- 達摩本草（薑黃相關產品，社群高聲量）
- BHK's（薑黃素食膠囊）
- DHC（濃縮薑黃，開架代購常見）
- 紅薑黃粉／小農自產（Dcard 懶人包熱議）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 心理治療（CBT／人際治療）
- 抗憂鬱藥物（SSRI 等）
- 規律運動
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-depression-INT-curcumin-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "薑黃素能改善憂鬱症",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 3,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟡 B 初步證據"
}
}